Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Gaucher disease type 2


Other Names for this Disease

  • Gaucher disease, acute neuronopathic type
  • Gaucher disease, infantile cerebral
  • GD 2
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Overview

Gaucher disease type 2 is an inherited metabolic disorder in which harmful quantities of a fatty substance called glucocerebroside accumulate in the spleen, liver, lungs, bone marrow, and brain. Liver and spleen enlargement are often apparent by 3 months of age. Patients typically develop extensive and progressive brain damage and many die by 2 years of age.[1] Gaucher disease type 2 is caused by mutations in the GBA gene. It is inherited in an autosomal recessive pattern.[2] While enzyme replacement therapy is available, there is no effective treatment for the severe brain damage that may occur in patients with this condition.[1]
Last updated: 2/22/2010

References

  1. NINDS Gaucher's Disease Information Page. National Institute of Neurological Disorders and Stroke (NINDS). 2009; http://www.ninds.nih.gov/disorders/gauchers/gauchers.htm. Accessed 2/22/2010.
  2. Gaucher disease. Genetics Home Reference (GHR). 2008; http://ghr.nlm.nih.gov/condition=gaucherdisease. Accessed 2/22/2010.
Your Questions Answered
by the Genetic and Rare Diseases Information Center

Please contact us with your questions about Gaucher disease type 2. We will answer your question and update these pages with new resources and information.

Basic Information

  • The American Society of Gene & Cell Therapy provides information on the treatment of lysosomal storage diseases.
  • Genetics Home Reference (GHR) contains information on Gaucher disease type 2. This website is maintained by the National Library of Medicine.
  • MedlinePlus was designed by the National Library of Medicine to help you research your health questions, and it provides more information about this topic.
  • The National Human Genome Research Institute's (NHGRI) mission encompasses a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. Click on the link to view the information page on this topic.
  • The National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Click on the link to view information on this topic.
  • The National Organization for Rare Disorders (NORD) is a federation of more than 130 nonprofit voluntary health organizations serving people with rare disorders. Click on the link to view information on this topic.

In Depth Information

  • Medscape Reference provides information on this topic. Click on the link to view this information. You may need to register to view the medical textbook, but registration is free.
  • MeSH® (Medical Subject Headings) is a terminology tool used by the National Library of Medicine. Click on the link to view information on this topic.
  • The Online Mendelian Inheritance in Man (OMIM) is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine. 
  • Orphanet is a European reference portal for information on rare diseases and orphan drugs.  Access to this database is free of charge.
  • PubMed is a searchable database of medical literature and lists journal articles that discuss Gaucher disease type 2. Click on the link to view a sample search on this topic.

Insurance Issues

Other Names for this Disease
  • Gaucher disease, acute neuronopathic type
  • Gaucher disease, infantile cerebral
  • GD 2
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.